Safety and Efficacy of Left Atrial Appendage Closure with the Amplatzer Cardiac Plug in Very High Stroke and Bleeding Risk Patients with Non-Valvular Atrial Fibrillation by unknown
ORIGINAL RESEARCH
Safety and Efficacy of Left Atrial Appendage Closure
with the Amplatzer Cardiac Plug in Very High Stroke
and Bleeding Risk Patients with Non-Valvular Atrial
Fibrillation
Julia Kebernik . John Jose . Mohamed Abdel-Wahab . Bjo¨rn Sto¨cker .
Volker Geist . Gert Richardt
To view enhanced content go to www.cardiologytherapy-open.com
Received: September 29, 2015 / Published online: November 13, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Limited data exist on the
outcomes after left atrial appendage closure
(LAAC) with the AmplatzerTM Cardiac Plug
(ACP; St. Jude Medical, Minneapolis, MN,
USA) in patients with atrial fibrillation (AF)
with very high stroke and bleeding risks, the
subset expected to benefit most from this
procedure. The objective of this study was to
report clinical outcomes after LAAC with the
ACP device in a very high stroke and bleeding
risk cohort of patients with non-valvular AF and
contraindications to oral anticoagulation
(OAC).
Methods: LAAC using the ACP device was
performed in 96 patients with AF who had
median CHA2DS2-VASc and HAS-BLED scores of
5 and 3, respectively. Post-procedure, patients
received dual antiplatelet therapy for 6 months.
A transesophageal echocardiography (TEE) was
scheduled at 6 months.
Results: Procedural success was 100%.
Procedural-related complications occurred in
7.3% (pericardial effusion, 4.2%; thromboembolic
events, 2.1%; device embolization, 1.0%).
Additional thromboembolic events occurred
in three patients during follow-up (92.7%
follow-up). After 93.4 patient-years of
follow-up, the annual rates of thromboembolic
and major bleeding events were 3.2% and 1.1%,
respectively. In those with TEE follow-up (70%),
complete LAAC with no leaks was observed.
Thrombus formation on the device was noted
on TEE in two patients.
Conclusion: LAAC using the ACP device was
associated with an acceptable low rate of
embolic and bleeding events after a median
follow-up of 9 months in a cohort of patients
with AF who were amongst the highest stroke
and bleeding risks reported so far in LAAC
trials.
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fibrillation; Left atrial appendage closure; Oral
anticoagulation; Stroke; Thromboembolism
Electronic supplementary material The online
version of this article (doi:10.1007/s40119-015-0053-z)
contains supplementary material, which is available to
authorized users.
J. Kebernik (&)  J. Jose  M. Abdel-Wahab 
B. Sto¨cker  V. Geist  G. Richardt
Heart Center, Segeberger Kliniken GmbH (Academic
Teaching Hospital of the Universities of Kiel,
Lu¨beck, and Hamburg), Bad Segeberg, Germany
e-mail: jkebernik@gmx.de
Cardiol Ther (2015) 4:167–177
DOI 10.1007/s40119-015-0053-z
INTRODUCTION
Embolic stroke is a serious complication in
patients with atrial fibrillation (AF) [1]. Oral
anticoagulation (OAC) is effective in reducing
rates of thromboembolism, albeit with an
increased bleeding risk [2, 3]. To identify
patients with a significant risk of stroke and
bleeding different risk stratification scores have
been developed. Whereas the CHA2DS2-VASc
score is recommended to evaluate the
individual stroke risk in patients with AF, the
HAS-BLED score was developed to assess the risk
of bleeding during anticoagulation treatment
[4]. Clinical trials have established the
predictive value of these scores [5]. In
day-to-day clinical practice, patients with the
highest risk of stroke are those with a previous
stroke, and patients with the highest risk of
bleeding are those with a previous bleeding
episode, especially the elderly. As risk factors for
stroke and bleeding commonly overlap,
management of patients with AF is still a
clinical challenge and many patients at
highest risk for stroke are not treated with
OAC, even after the introduction of direct
thrombin and factor Xa inhibitors.
New interventional therapies have been
developed for stroke prevention in
non-valvular AF. As about 90% of the thrombi
originate from left atrial appendage (LAA) [6],
LAA closure (LAAC) devices were developed to
prevent thromboembolic events and to avoid
long-term OAC.
Of these LAAC devices, the WatchmanTM
device (Boston Scientific, Marlborough, MA,
USA) is the one that has been well studied. A
recent meta-analysis has provided supportive
data for the efficacy and safety of intervention
with this device in patients with AF [7]. However,
the observed effects were not uniformly in favor
of the Watchman device: When compared with
warfarin therapy at 2–3 years’ follow-up, LAAC
was associated with a decreased likelihood of
hemorrhagic stroke, cardiovascular death, and
non-procedural bleeding, while the rates of
ischemic stroke were higher [7]. The most
commonly used device in Europe is the
AmplatzerTM Cardiac Plug (ACP; St. Jude
Medical, Minneapolis, MN, USA). A few studies
that have been published with the ACP indicate a
safe implantation with low rates of
procedural-related complications [8–11]. Recent
reports also suggest a reduction of stroke risk
when compared to the expected stroke rate based
on the CHA2DS2-VASc score [9–11].
Theoretically, the benefit of LAAC therapy
should be more pronounced in patients with
higher stroke and bleeding risks. The aim of the
current analysis was to assess safety and efficacy
of LAAC with the ACP device in a cohort of very
high stroke and bleeding risk patients with
contraindications for OAC.
METHODS
This was a retrospective observational cohort
analysis of a single German center database of
LAAC with the ACP device. Patients with
non-valvular-AF, a CHA2DS2-VASc score C2, and
contraindications to OAC therapy including
previous major bleeding, thromboembolic
events while on OAC, high tendency to fall,
intolerance and non-compliance to OAC, and
labile international normalized ratio (INR) were
included.
The study cohort comprised 96
consecutive patients, who underwent LAAC
with the ACP between March 2009 and
December 2014.
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Procedure
Prior to the procedure, transthoracic and
transesophageal echocardiography (TTE and
TEE, respectively) were performed to exclude
intracardiac thrombi, determine LAA anatomy,
and record baseline parameters.
The procedure was performed under mild
sedation (intravenous propofol and
midazolam) with angiographic and TEE
guidance. Access to the left atrium (LA) was
gained by transseptal puncture using a
Brockenbrough needle (Cook Medical,
Bloomington, IN, USA) and a transseptal
sheath (Cook Medical). Septum was imaged
by TEE in a bicaval and a short axis view, and
an inferior and posterior site was chosen for
optimal LAA access. After puncture, heparin
was administered at a dose of 70–100 U/kg to
achieve an activated clotting time of at least
250 s. The sheath was then introduced into
LAA and angiography performed by manual
contrast injection. LAA measurements were
obtained by TEE and angiography (Fig. 1a). In
different projections, diameters of LAA
ostium, landing zone, and length were taken.
Sizing was based on the dimensions of the
landing zone. The device was oversized by
about 4 mm with respect to the LAA landing
zone.
Then, the ACP device was introduced and
placed in the LAA using a dedicated delivery
system, the Amplatzer TorqVueTM 45 9 45
delivery sheath (AGA Medical Corp.,
Plymouth, MN, USA). Before releasing the
device, stability was assessed (Minnesota
wiggle maneuver, TEE, and angiographic
evaluations; Fig. 1b, c). Assessments were made
for any pericardial effusion during the
procedure.
In all cases, intravenous ciprofloxacin
(400 mg) was administered during the
procedure. Dual antiplatelet therapy (DAPT)
consisting of aspirin (100 mg) and clopidogrel
(75 mg) were given for at least 6 months unless
there was a contraindication. After 6 months,
single antiplatelet therapy was recommended
lifelong. Postprocedural TTE evaluation was
done to rule out pericardial effusion and to
confirm proper device position.
Fig. 1 Key steps of ACP implantation. a Angiographic measurement of the landing zone. b Angiography conﬁrmation of
an optimal position with no residual leak. c Post-release cine image frame of the device
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Follow-up
Clinical follow-up was carried out during
hospital visit or through phone contact at
6 months and 1 year. Patients were scheduled
a TEE at 6 months follow-up to assess the
presence of a thrombus and a residual leak
(mild \1 mm, moderate 1–3 mm, severe
[3 mm).
Endpoints
Procedural success was defined as successful
implantation of the ACP in LAA with no
residual leak by angiographic and
echocardiographic evaluation.
Complications that occurred during the
procedure/hospitalization and during the
clinical follow-up were documented. They
were defined as: thromboembolic event
(transient ischemic attack (TIA), stroke, and
systemic embolism), major bleeding (Bleeding
Academic Research Consortium [BARC] type
C3b) [12], device embolization, myocardial
infarction, and all-cause mortality.
Statistical Methods
Continuous variables were expressed as
mean ± standard deviation and as median
(interquartile range) depending on the data
and its distribution. Categorical variables were
reported as counts (percentages). Efficacy of the
device to prevent thromboembolic events was
tested by comparing the actual event rate at
follow-up with the CHA2DS2-VASc score [4, 5]
estimated event rates. The average annual risk
for the whole study population was calculated.
The total number of thromboembolic events
during follow-up period was divided by the total
patient-years of follow-up and was multiplied
by 100 to get the actual annual rate of
thromboembolism. Risk reduction of
thromboembolism was calculated as follows:
(estimated percent event rate-actual percent
event rate)/estimated percent event rate.
Bleeding risk reduction was assessed
analogous to stroke risk reduction. The annual
event rate at follow-up was compared with the
HAS-BLED score [13, 14] estimated event rates.
Comparisons between observed and predicted
thromboembolic and bleeding event rates were
assessed using binomial tests. Rate ratios with
95% Poisson exact confidence intervals of
observed and expected rates were also
calculated. STATA version 14 (StataCorp LP,
College Station, TX, USA) and GraphPad Prism
6 (GraphPad Software, Inc., La Jolla, CA, USA)
were used for the statistical analysis.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed written consent for the
procedure was obtained from all patients.
RESULTS
A total of 96 consecutive patients were included
in this study. Patient’s baseline characteristics
are summarized in Table 1. Mean age of the
study population was 76 ± 7 years and 39.5%
were female. AF was permanent in 52%,
persistent in 25%, and paroxysmal in the
remainder. Sixty-three patients (65.5%) had a
previous stroke and 59 patients (61.4%) had a
history of major bleeding. One-fifth of the
patients had a concomitant history of stroke
and bleeding. The median (interquartile range)
CHA2DS2-VASc score was 5 (4.25–7) and the
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median (interquartile range) HAS-BLED score
was 3 (3–4). A history of major bleeding was the
principal contraindication for OAC and
consequent LAAC. Other indications for LAAC
were high tendency to fall (n = 12, 12.5%), and
intolerance as well as non-compliance for OAC
(n = 6, 6.2%). Notably in 16 (16.6%) patients,
LAAC was performed because of
thromboembolic events while on OAC.
Procedural Outcome
Successful device implantation was achieved in
all patients (n = 96, 100%). The mean
procedural time was 46 ± 5 min. The most
commonly used device size was 24 mm
(n = 34, 35.5%). LAAC was possible with the
initial chosen device in 91 patients (95%). In
five patients, device release criteria were not
met and another device size was chosen (smaller
sized device in four cases). LAAC was not
combined with other procedures.
Procedural-related complications occurred in
seven patients (7.3%) and are listed in Table 2.
Pericardial effusion requiring pericardiocentesis
was the most common complication and
occurred in four patients (4.2%). None of the
patients required surgical intervention. Device
embolization occurred in one patient; the
device embolized into the LA (Fig. 2), where it
was snared out, reintroduced and successfully
implanted.
There were two cases with a thromboembolic
event (2.1%): One TIA (this was associated with
device embolization) and one stroke that was
attributed to hypotension. There were no
procedural-related myocardial infarctions or
deaths.
Follow-up Outcomes
Clinical follow-up was available in 89 patients
(92.7%) with a median (interquartile range)
follow-up duration of 9 months
(6–18 months). Eighteen patients (20%) were
followed up for more than 20 months, and for
35 patients (39.3%) at least 1-year follow-up was
available.
Table 1 Baseline characteristics of the study population
(n = 96)
Characteristic Value










Congestive heart failure 19 (19.7)
Hypertension 93 (96.8)
Diabetes mellitus 30 (31.2)
Previous stroke 63 (65.5)
Vascular disease 64 (66.6)
CHADS2 score, median (interquartile range) 4 (3–4.75)
HAS-BLED score, median (interquartile
range)
3 (3–4)
History of bleeding 59 (61.4)
Intracranial 35 (59.1)
Gastrointestinal 17 (28.7)
Other (urethral, ophthalmological, severe
hematoma)
7 (11.8)
Thromboembolic events on OAC 16 (16.6)
High tendency to fall 12 (12.5)
Intolerance and non-compliance to OAC 6 (6.2)
Labile INR 3 (3.1)
Data expressed as number (%) unless otherwise stated
OAC oral anticoagulants, INR International normalized
ratio, SD standard deviation
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After 93.4 patient-years of follow-up, a total
of 13 events (14.6%) were recorded (Table 3).
Three of them were thromboembolic events:
One TIA and two strokes. One TIA occurred
after 18 months in an 89-year-old male patient
who had a previous ischemic stroke
(CHA2DS2-VASc score = 6) as well as an
intracranial bleeding event (HAS-BLED
score = 5). TEE did not reveal thrombus on the
device.
In a 76-year-old female patient with previous
stroke (CHA2DS2-VASc score = 5), cranial
computed tomography showed a sub-acute
posterior inferior cerebellar arterial (PICA) and
superior cerebellar artery (SCA) infarction on
the left side 20 months after ACP implantation.
This patient had no TEE follow-up.
Cardioembolic stroke was the clinical
diagnosis made by neurologists in both these
cases.
Another patient, a 75-year-old with previous
history of stroke (CHA2DS2-VASc score = 5), had
a recurrent stroke 14 months after ACP
implantation while on aspirin. Magnetic
resonance imaging confirmed an acute
right-sided thalamic infarct and showed
microangiopathic disease. TEE did not reveal
thrombus on the device in this patient as well.
Major bleeding occurred in one patient at
follow-up. An 82-year-old male with a
HAS-BLED score of 5 experienced an
intracranial bleeding, caused by a fall
26 months after device implantation, while on
aspirin. One patient experienced a clinically
significant pericardial effusion 11 months after
the procedure. A total of nine patients died
during follow-up (Table 3).
TEE Outcomes
Sixty-two patients (70%) with clinical follow-up
had a TEE evaluation after a mean duration of
8.6 months. None of the patients had a residual
leak. Thrombus formation on the device was
observed in two cases (3.2%), 5 and 6 months
after LAAC. Both of them were on DAPT. The
presence of thrombus did not correlate with a
clinical event. In both of the patients, thrombus
resolved after 5 and 6 weeks of OAC therapy.




Major bleeding 4 (4.2)
Pericardial effusion 4 (4.2)
Other major bleeding 0 (0.0)
Thromboembolic events 2 (2.1)
Stroke 1 (1)
Transient ischemic attack 1 (1)
Systemic embolization 0 (0.0)
Device embolization 1 (1.0)
Myocardial infarction 0 (0.0)
Death 0 (0.0)
Fig. 2 Device embolization. Intraprocedural trans-
esophageal echocardiography: embolization of the device
into the left atrium
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DISCUSSION
The prevention of thromboembolism is the
most important therapeutic goal in patients
with AF. Vitamin K antagonists (VKA)
effectively reduce strokes rates [2], but as
individual stroke and bleeding risks increase in
parallel, physicians face a therapeutic dilemma
concerning their use in very high stroke and
bleeding risk patients.
One effective alternative to VKA are the
novel oral anticoagulants (NOACs), i.e.,
dabigatran, rivaroxaban, apixaban, and
edoxaban [15–17], whose main toted benefit
in comparison to VKA is reduction of
intracranial bleeding. But major bleedings still
occur with these agents, especially in the elderly
with renal impairment, and so far specific
antidotes such as idarucizumab [18] are still in
their investigational stage or undergoing phase
three trials. In this context, the
non-pharmacological treatment option of
LAAC—which offers simultaneous advantages
of stroke reduction as well as avoidance of
long-term OAC—gains prominence.
The PLAATO System (ev3, Plymouth, MN,
USA) was the first dedicated LAAC device [19].
This device was succeeded by the Watchman
device, whose safety and efficacy were proved in
two large randomized trials. The PROTECT AF
(ClinicalTrials.gov identifier, NCT00129545)
[20] and the PREVAIL (ClinicalTrials.gov
identifier, NCT01182441) [21] trial were
non-inferiority trials that evaluated the
Watchman device compared with warfarin in
patients with AF who were eligible to take OAC.
As stroke prevention strategies are particularly
challenging in patients who are ineligible to
take OAC, the ASAP study (ClinicalTrials.gov
identifier, NCT00851578) [22] was designed.
This small, non-randomized trial documented
a reasonable safety profile over short-term
follow-up for the Watchman device.
Current available data with the ACP are
derived from several small, observational
studies [8–11]. In contrast to the Watchman
trials, most of the patients enrolled in these
studies were not suitable for long-term OAC and
were treated with DAPT post-implantation. The
largest conducted study so far on the ACP
device was recently published in 2015 by
Tzikas et al. [11], which was a multicenter trial
of 1047 patients that established its safety and
efficacy.
Because LAAC makes long-term OAC
unnecessary, patients with very high stroke
and bleeding risks should benefit most from
this therapy. Nevertheless, LAAC carries
inherent hazards especially in the
periprocedural period and therefore a net
clinical benefit of LAAC has to be established
even in this particular subset of patients.
Table 3 Follow-up outcome (total patients with
follow-up, n = 89)
Outcome n (%)
Total 13 (14.6)
Thromboembolic events 3 (3.4)
Stroke 2 (2.2)
Transient ischemic attack 1 (1.1)
Systemic embolism 0 (0.0)
Major bleeding 1 (1.1)
Intracranial bleeding 1 (1.1)
Myocardial infarction 0 (0.0)
Device embolization 0 (0.0)
Death 9 (10.1)
Cardiovascular cause 1 (1.1)
Other 3 (3.4)
Unknown 5 (5.6)
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Our study population represents a very
high-risk cohort of patients with AF with
respect to stroke and bleeding, given the high
median CHA2DS2-VASc score and HAS-BLED
score of 5 (mean = 5.6) and 3 (mean = 3),
respectively. The frequency of a previous
stroke and bleeding episode were as high as
65.5% and 61.4%, respectively; 20% had a
concomitant history of both events.
Comparing stroke and bleeding risk with
previous published studies, this study cohort is
amongst the highest stroke and bleeding risks
reported so far. In comparison, the mean
CHA2DS2-VASc score of the study population
in the PROTECT AF trial was 3.5; 18.5% had a
previous stroke [7]. In the largest study reported
so far with the ACP device, the mean
CHA2DS2-VASc score was 4.4 with a history of
previous stroke in 39% [11].
Procedural Outcomes
Our study confirms the results of previous
studies: LAAC with the ACP has a high rate of
procedural success and an acceptable rate of
periprocedural complications. In recently
reported studies, periprocedural complications
were similar to those observed in our study,
namely pericardial effusion, thromboembolic
events, and device embolization. Postulated
reasons for pericardial effusion are transseptal
puncture related, extensive manipulation
within the LAA, device recapture and
repositioning, stiff wire exchange in the LAA,
and extensive oversizing of the device [23, 24].
Pericardiocentesis alone seems to be sufficient
enough to control this complication, its
occurrence should decrease with more
technical experience.
Device embolization is a well-known
complication of LAAC with an average
reported rate of less than 4% [25]. In our
study, the device was successfully captured by
a gooseneck snare. Our experience is in
agreement with previous published cases of
device embolization, which show that device
embolizations into the LA can be successfully
managed percutaneously. The reason for
embolization in our case is unclear since this
occurred despite ensuring a stable and safe
device position. After retrieval, the same
device was reintroduced and reimplanted
successfully. Nonetheless, device embolization
is a serious complication and more knowledge
regarding its mechanisms is necessary.
Device Efficacy
Thromboembolic events during follow-up were
observed at an annual rate of 3.2%. Comparing
this observed rate with the estimated annual
risk of 6.7–10.0% for patients without warfarin
and with a CHA2DS2-VASc score of 5, a 52–68%
reduction was calculated (Fig. 3). Rate ratio for
incidence of thromboembolic events was 0.32
(95% CI 0.07–0.94), assuming estimated annual
risk to be 10%. Reduction of thromboembolic
events with ACP device in other case series
varies from 59% to 80% [9–11]. Variabilities in
risk reduction seem to be influenced by clinical
characteristics of the patients including the
CHA2DS2-VASc score. It must also be
considered that when comparing risk
reduction rates across different studies, the
values of the expected stroke rate for a given
CHA2DS2-VASc score used in the calculation of
the relative risk reduction were not the same.
Our results have confirmed that the reduction
of thromboembolic events with the ACP device
is significant even in very high stroke risk
patients with AF, the derived magnitude of the
benefit being large.
During the follow-up period, one patient had
a fall-related intracranial bleeding and was
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classified as major bleeding event, but in reality
was an event unrelated to the device. Apart
from this patient, there were no overt bleeding
events recorded during follow-up. Comparing
an annual rate of 1.1% bleeding episodes during
follow-up in our study with the estimated
annual bleeding risk of 3.74–5.8% for patients
on warfarin with a HAS-BLED score of 3, a
70–81% reduction of the bleeding risk was
calculated (Fig. 3). Rate ratio for incidence of
bleeding events was 0.18 (95% CI 0.00–1.03),
assuming estimated annual risk to be 5.8%.
Of interest in our study was the presence of
device-related thrombus, which was not
associated with any thromboembolic events.
The two patients who had thrombi on the
device were on DAPT at the time of
diagnosis (mean 5.5 months post-implant).
Device-related thrombus was reported in other
LAAC studies as well, although association with
clinical stroke was rare. In the PROTECT AF
study [25], device-associated thrombi were
observed in 4.2%, and thrombus-associated
annualized stroke rate was 0.3%. Interestingly,
the rate of device-related thrombus in PROTECT
AF was similar to that of ACP, despite the fact
that patients were on OAC 45 days
post-implant. In all cases reported so far,
short-duration OAC therapy or low molecular
weight heparin were effective in resolving
thrombi.
Study Limitations
This study has all the limitations of a
single-center retrospective observational study.
The sample size of the study was small and no
inference about comparative outcomes can be
made due to lack of a control group. The annual
stroke rate of our population was compared
with the estimated events based on the
CHA2DS2-VASc score. Because the expected
events are based on historic controls and not
validated in the current study population, the
possibility of a type I error cannot be ruled out.
For the above reasons, randomized controlled
trials are needed for further validation of the
results. It must be pointed out that patients of
our study were on DAPT for 6 months after the
procedure. DAPT has been reported to reduce
Fig. 3 Effectiveness in risk reduction of thromboembolism
and bleeding. Observed annual rates of thromboembolism
and bleeding events in the study population during
follow-up period compared with the expected rate based
on CHA2DS2-Vasc and HAS-BLED score. Arrows indicate
risk reductions of events compared to expected event rates
obtained from earlier studies
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stroke risk. This was not considered when
comparing expected and observed stroke rates,
and hence an inflated benefit cannot be ruled
out. Finally, echocardiographic follow-up was
incomplete and events such as minimal leaks or
device thrombosis may have been missed.
CONCLUSIONS
LAAC with the ACP appears to be effective with
acceptable rates of periprocedural complications
and low rates of thromboembolic and bleeding
events at follow-up in a cohort of very high stroke
and bleeding risk patients with AF. With growing
experience, this new technology of LAAC using
ACP may become a valid alternative for high-risk
patients with AF with contraindication for OAC.
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